KOSPIBiotech & Pharma002390

Handok

₩8,260▲ 0.36%2026-11-18 close
Market Cap
₩113.7B
Turnover
₩18,011,860
Volume
2.2K
Shares out.
13.8M
PER
—
PBR
0.4×
EPS
-₩1,666
Dividend Yield
2.44%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit back in the black, net losses persist

Operating profit rose for two consecutive quarters in 2Q and 3Q 2026, but net losses attributable to controlling shareholders have continued for three straight quarters from 1Q 2026, and a larger financial loss keeps bottom-line profit in the red.

  1. 1

    3Q 2026 revenue was KRW 142.4 billion, down 1.5% year on year, while operating profit was KRW 4.47 billion, up 2,352.0% year on year.

  2. 2

    Annual operating profit bottomed at KRW 539 million in 2024 and recovered to KRW 3.29 billion in 2025, but the company still posted a net loss attributable to controlling shareholders of KRW 2.15 billion, extending its losses to three straight years since 2023.

  3. 3

    Financial losses are weighing on bottom-line results. The cumulative financial loss through 3Q 2026 was about KRW 26.1 billion in the preliminary release, roughly four times the operating profit.

  4. 4

    Newly licensed anticancer drugs Elroxatin and Zaltrap, the OTC pain reliever Ketotop and the continuous glucose monitor Barozen Fit are cited as the main drivers of operating improvement.

  5. 5

    The debt ratio rose from 128.1% in 2022 to 184.1% in 2025, and total liabilities at the end of 2025 were KRW 512.4 billion.

02

Business structure

Handok operates across prescription drugs, OTC drugs, and medical devices and diagnostics. In the preliminary separate-basis results for 1H 2026, prescription drug sales were KRW 177.2 billion, about 66% of the total.

Within prescription drugs, the anticancer drugs Elroxatin and Zaltrap, licensed in January 2026, became new revenue sources, while the diabetes drug Tenelia and the hypertension drugs Afrobasc and Afrobel also grew.

The core OTC product is the topical analgesic Ketotop, whose sales rose from KRW 39.4 billion in 2024 to KRW 44.3 billion in 2025. In medical devices and diagnostics, the continuous glucose monitor Barozen Fit reached KRW 3.3 billion in 1H 2026, up 142%.

Contract manufacturing (CMO) is another pillar, with CMO sales of about KRW 40 billion in 2025, up 13% year on year. Rare disease drug sales were KRW 6.2 billion in 1H 2026, up 42.4%.

Handok previously saw a revenue gap when its rights to Soliris and Ultomiris were recovered, and those two products accounted for 10.07% of 2021 sales. One company profile dataset puts the pharmaceutical manufacturing and sales segment at about 77.64% of revenue. Handok is positioned alongside prescription-focused listed companies such as Yuhan and Hanmi Pharm.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩144.7B₩200M0.1%
2025Q4₩140.1B₩4.5B3.2%
2026Q1₩135.4B₩800M0.6%
2026Q2₩140.7B₩2.8B2.0%
2026Q3₩142.4B₩4.5B3.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩543.8B₩28.5B₩10.7B5.2%2.8%128.1%
2023₩522.7B₩12.6B-₩28.8B2.4%−8.5%132.0%
2024₩507.4B₩500M-₩52.6B0.1%−18.3%172.8%
2025₩535.1B₩3.3B-₩2.2B0.6%−0.8%184.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results moved from a peak in 2022 to a trough in 2024 and a recovery in 2025. Revenue fell from KRW 543.8 billion in 2022 to KRW 522.7 billion in 2023 (down 3.9% year on year) and KRW 507.4 billion in 2024 (down 2.9%), then rose to KRW 535.1 billion in 2025 (up 5.5%).

Among 2022 to 2025, 2022 was the largest year and 2024 the smallest. Operating profit fell from KRW 28.5 billion in 2022 to KRW 12.6 billion in 2023 (down 55.9%) and KRW 539 million in 2024 (down 95.7%), then recovered to KRW 3.29 billion in 2025 (up 511.2%).

The operating margin dropped from 5.2% in 2022 to 0.1% in 2024 before edging up to 0.6% in 2025.

Net income attributable to controlling shareholders swung from KRW 10.7 billion in 2022 to a net loss of KRW 28.8 billion in 2023 and a larger net loss of KRW 52.6 billion in 2024, narrowing to a net loss of KRW 2.15 billion in 2025, which marks three consecutive loss years since 2023.

Net income including non-controlling interests followed the same direction, from KRW 10.6 billion in 2022 to a net loss of KRW 2.24 billion in 2025. Operating cash flow was KRW 30.5 billion in 2022 and KRW 36 billion in 2023, turned negative at KRW 2.79 billion in 2024, and recovered to KRW 3.98 billion in 2025.

On a quarterly basis, net income attributable to controlling shareholders of KRW 7.94 billion in 4Q 2025 turned into a net loss of KRW 8.55 billion in 1Q 2026. Revenue bottomed at KRW 135.4 billion in 1Q 2026 and rose to KRW 140.7 billion in 2Q and KRW 142.4 billion in 3Q.

Newly licensed anticancer drugs, Ketotop and the glucose monitor were cited as drivers of the 3Q 2026 operating profit gain. Quarterly revenue was also weighed by the end of a flu vaccine business that had contributed in the prior-year period. The main reason for the bottom-line loss is the financial segment.

Cumulative financial losses through 3Q 2026 were about KRW 26.1 billion in the preliminary release, a deterioration of about KRW 27.5 billion from the prior-year period, according to one analysis. Quarterly results swing widely, so a single quarter is too early to read as a trend.

05

Industry analysis

Korean pharmaceutical listings split between companies centered on prescription drugs and those combining OTC drugs with diagnostics. Handok's prescription share of about 66% in 1H 2026 places it closer to the prescription-focused model.

Large biotech names such as Samsung Biologics and Celltrion focus on biopharmaceutical manufacturing and biosimilars, so their business models limit direct comparison. In prescription drugs and new drug competition, mid-sized domestic peers such as Yuhan and Hanmi Pharm are the main reference points.

Handok is building its pipeline through new drug development and open innovation. Rare disease drug sales rose 42.4% in 1H 2026, reflecting demand for high-priced specialty treatments. Continuous glucose monitoring is a fast-growing area, as Barozen Fit's 142% growth in 1H 2026 shows.

The OTC business depends on Ketotop, and its results have moved with sales channel changes and product renewals in the past. Its position in the industry cycle differs by product line, and Handok is pursuing both licensed-in products and its core in-house products.

06

Outlook

The nearest checkpoint is the phase 3 result for RZ358, a treatment for hyperinsulinism from an affiliate, which was reported as scheduled for 2H 2026. ABL111, whose domestic development and commercialization rights Handok holds, is being prepared for a global phase 3 trial by ABL Bio.

Handok has said it plans to raise productivity and quality competitiveness in its CMO business and to improve manufacturing cost efficiency to build a base for contract manufacturing and global customer expansion. Ketotop sales reached KRW 35.5 billion for the nine months through 3Q 2026, up 21.2% year on year.

Growth in newly licensed anticancer drugs is already visible in the 1H 2026 results. Reducing the financial burden, alongside higher sales from new products, is cited as key to improving results.

The 4Q 2026 preliminary results are expected around early 2027, when operating profit trends and the size of financial gains and losses can be checked together. The 2026 annual report will confirm full-year operating margin and debt ratio.

07

Valuation

PER
—
PBR
0.4×
ROE
-8.3%
EPS
-₩1,666
BPS
₩18,510
Dividend per share
₩200

The price-to-earnings ratio cannot be calculated because the combined net loss attributable to controlling shareholders over the last four quarters is KRW 21.1 billion. The price-to-book ratio is below 1x, meaning the share price sits at a low level relative to book net assets.

The composition of those net assets, however, has to be read together with the debt structure. The debt ratio rose from 128.1% in 2022 to 184.1% in 2025. In earnings, the direction is a narrowing of losses, from a net loss attributable to controlling shareholders of KRW 52.6 billion in 2024 to KRW 2.15 billion in 2025.

A low multiple relative to net assets becomes more meaningful when read alongside the pace of earnings recovery. Dividend yield moves with the share price, so it should be read separately from the earnings trend.

The price-to-earnings ratio can be recalculated once the combined results of the last four quarters return to a profit.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Growing contribution from new anticancer drugs

Elroxatin, launched in January 2026, booked KRW 8.1 billion in 3Q 2026 sales, and Zaltrap added KRW 700 million. Combined sales of the two drugs reached KRW 17.5 billion in 1H 2026. Their growth led the prescription drug gains in the first half, which is the core bull argument.

Steady growth in Ketotop and Barozen Fit

Ketotop grew from KRW 39.4 billion in 2024 to KRW 44.3 billion in 2025, and its cumulative sales through 3Q 2026 reached KRW 35.5 billion, up 21.2% year on year. Barozen Fit posted KRW 3.3 billion of sales in 1H 2026, up 142%. Both products were cited as reasons for the 3Q operating profit improvement.

Quarterly recovery in operating profit

Operating profit reached KRW 753 million in 1Q 2026 before rising to KRW 2.77 billion in 2Q and KRW 4.47 billion in 3Q, two consecutive quarterly gains. Year on year, 3Q 2026 operating profit rose 2,352.0%. Operating cash flow turned positive in 2025 at KRW 3.98 billion after a negative year in 2024.

09

Bear factors

Persistent net losses attributable to controlling shareholders

Net income attributable to controlling shareholders was negative for three consecutive years from 2023 to 2025, and posted losses for three straight quarters from 1Q to 3Q 2026. The combined net loss attributable to controlling shareholders over the last four quarters is KRW 21.1 billion. The fact that operating gains have not translated into net profit is the core bear argument.

Financial losses driving a gap with net income

According to one analysis of the preliminary 3Q 2026 release, the cumulative financial loss of about KRW 26.1 billion is roughly four times operating profit. The deterioration in financial results is identified as the main route by which the net loss widened. The specific items and size of the financial loss should be verified against figures in the 2026 annual report.

Stalled revenue growth

Revenue for 3Q 2026 was KRW 142.4 billion, down 1.5% year on year. Reports attribute part of the decline to the end of a flu vaccine business that had contributed in the prior-year period. Annual revenue in 2025 was KRW 535.1 billion, still below the KRW 543.8 billion recorded in 2022.

10

Risk factors

Pipeline clinical outcomes

The phase 3 result for RZ358 from an affiliate is scheduled for 2H 2026, and the valuation of the pipeline could change depending on the outcome. ABL111 is preparing to enter a global phase 3 trial. A delay in the trial or a disappointing result could extend the financial strain.

Dependence on licensed-in products and rights

Handok previously lost high-revenue products when the rights to Soliris and Ultomiris were recovered, and those two products accounted for 10.07% of 2021 sales. As sales from newly licensed anticancer drugs grow, the end of a licensing agreement could create a similar revenue gap.

Financial and balance sheet burden

A worse financial result combined with a rising debt ratio could slow the recovery in net income. Total liabilities at the end of 2025 were KRW 512.4 billion, and total equity was KRW 278.3 billion. The next step is to check the specific causes and size of the financial loss in the 2026 annual report.

11

What to watch next

  1. 2H 2026 (date TBD)

    Phase 3 results for RZ358 from an affiliate. This is the key dataset for judging the value of the hyperinsulinism pipeline.

  2. After 2H 2026 (timing TBD)

    Whether and when ABL111 enters its global phase 3 trial. This is the checkpoint for whether the pipeline expands.

  3. Around January to February 2027 (date TBD)

    The 4Q 2026 preliminary results. Check whether operating profit gains continue and how much the financial result narrows the net loss.

  4. By end of March 2027 (filing deadline)

    Filing of the 2026 annual report. It confirms full-year operating margin, debt ratio and financial results as audited figures.

12

Overall view

Handok showed improvement at the operating level. Operating profit rose for two consecutive quarters, from KRW 753 million in 1Q 2026 to KRW 2.77 billion in 2Q and KRW 4.47 billion in 3Q, with newly licensed anticancer drugs, Ketotop and Barozen Fit cited as contributors.

Net income attributable to controlling shareholders, however, has been negative for three straight quarters from 1Q to 3Q 2026, with a combined net loss of KRW 21.1 billion over the last four quarters.

A larger financial loss, exceeding operating profit, is identified as the direct factor blocking bottom-line improvement. On the balance sheet, the debt ratio rose from 128.1% in 2022 to 184.1% in 2025. In the pipeline, the RZ358 phase 3 result is scheduled for 2H 2026 and is a key checkpoint.

The bull case rests on core business strength and growth in licensed-in anticancer drugs, while the bear case rests on financial results and debt burden. The next checkpoints are the 4Q 2026 preliminary results and the 2026 annual report, where the focus will be how far financial results and operating margin improve.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. vegannews.co.kr
  2. sportalkorea.com
  3. kpanews.co.kr
  4. etoday.co.kr
  5. supple.kr
  6. news1.kr
  7. medipana.com
  8. edaily.co.kr
  9. etoday.co.kr
  10. supple.kr
  11. m.news.nate.com
  12. medipana.com
  13. smedaily.co.kr
  14. medicopharma.co.kr
  15. v.daum.net
  16. comp.wisereport.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis